Nilufer Cakir

Dr. Nilufer Cakir

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Ali ZarrabiAli Zarrabi
Ali Zarrabi
DPDavid Perrin
David Perrin
MKMahboubeh Kavoosi
Mahboubeh Kavoosi
MSMicah Sommer
Micah Sommer
SSSerap Sezen
Serap Sezen
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
Rhabdomyosarcoma is a rare cancer arising in skeletal muscle that typically impacts children and young adults. It is a worldwide challenge in child health as treatment outcomes for metastatic and recurrent disease still pose a major concern for both basic and clinical scientists. The treatment strategies for rhabdomyosarcoma include multi-agent chemotherapies after surgical resection with or without ionization radiotherapy. In this comprehensive review, we first provide a detailed clinical understanding of rhabdomyosarcoma including its classification and subtypes, diagnosis, and treatment strategies. Later, we focus on chemotherapy strategies for this childhood sarcoma and discuss the impact of three mechanisms that are involved in the chemotherapy response including apoptosis, macro-autophagy, and the unfolded protein response. Finally, we discuss in vivo mouse and zebrafish models and in vitro three-dimensional bioengineering models of rhabdomyosarcoma to screen future therapeutic approaches and promote muscle regeneration.

1 April 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MYMeral Yüce
Meral Yüce
FSFatma Sert
Fatma Sert
MTMilad Torabfam
Milad Torabfam
APAyhan Parlar
Ayhan Parlar
BGBUSRA GUREL
BUSRA GUREL
YÇYılmaz Çapan
Yılmaz Çapan

13 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Ali ZarrabiAli Zarrabi
Ali Zarrabi
DPDavid Perrin
David Perrin
MKMahboubeh Kavoosi
Mahboubeh Kavoosi
MSMicah Sommer
Micah Sommer
SSSerap Sezen
Serap Sezen
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
Rhabdomyosarcoma is a rare cancer arising in skeletal muscle that typically impacts children and young adults. It is a worldwide challenge in child health as treatment outcomes for metastatic and recurrent disease still pose a major concern for both basic and clinical scientists. The treatment strategies for rhabdomyosarcoma include multi-agent chemotherapies after surgical resection with or without ionization radiotherapy. In this comprehensive review, we first provide a detailed clinical understanding of rhabdomyosarcoma including its classification and subtypes, diagnosis, and treatment strategies. Later we focus on chemotherapy strategies for this childhood sarcoma and discuss the impact of three mechanisms that are involved in chemotherapy response including apoptosis, macro-autophagy, and the unfolded protein response. Finally, we discuss in vivo mouse and zebrafish models, and in vitro 3-dimensional bioengineering models of Rhabdomyosarcoma to screen future therapeutic approaches and promote muscle regeneration.

2 May 2025 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
NCNilufer Cakir
Nilufer Cakir
BABurcu Okmen Altas
Burcu Okmen Altas
Gokce Dicle KalayciogluGokce Dicle Kalaycioglu
Gokce Dicle Kalaycioglu
Nur MustafaogluNur Mustafaoglu
Nur Mustafaoglu
NANihal Aydogan
Nihal Aydogan

1 January 2024 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
NCNilufer Cakir
Nilufer Cakir
NONaile Ozturk
Naile Ozturk
AKAsli Kara
Asli Kara
Ali ZarrabiAli Zarrabi
Ali Zarrabi
Nur MustafaogluNur Mustafaoglu
Nur Mustafaoglu
This study delves into the optimization of niosomal production for biological applications, focusing on their emerging role as amphiphilic nanoparticles derived from nonionic surfactants, poised at the forefront of biomedical research. We aimed to formulate and characterize a diverse array of niosomal nanoparticles, with particular emphasis on process‐related parameters and physicochemical characteristics. Critical thresholds for size, polydispersity, and zeta potential were established to identify parameters crucial for optimal niosomal formulations through a comprehensive investigation of concentrations, sonication times, ingredient ratios, and surfactant types. Leveraging MODDE software, we generated 10 optimized formulations from preliminary parameter screening. The proposed experimental model design by the software exhibited acceptable similarity to the obtained experimental results (F‐score: 0.83). The criteria for selection of the predicted experimental model formed based on targeted physicochemical considerations. To enhance half‐life and penetration, especially in higher electrostatic regions like the central nervous system (CNS), we proposed a neutralized surface charge (−10 to 10 mV) while maintaining size within 100–200 nm and polydispersity below 0.5. Extended stability screening revealed periodic and extended Gaussian distributions for size and zeta potential to minimize flocculation and coagulation caused by neutralized surface charge. Notably, the cellular response performance of optimized niosomes was assessed via cellular binding, uptake, and viability in comparison with liposomes. Glioblastoma cell line (U‐87) and granulocyte colony‐stimulating factor (G‐CSF) containing lymphoblastic leukemia cell line (NFS‐60) were chosen to represent tumors developed in the CNS region and white blood cells, respectively, enabling a comprehensive comparative analysis with liposomes. The meticulous comparison between niosomes and liposomes revealed comparable cellular viability profiles on both U‐87 and NFS‐60 cell lines, highlighting their similarities in cellular interactions. Moreover, selected niosomal formulations demonstrated exceptional cellular uptake, either equaling or surpassing observed liposomal uptake. One of the most promising niosomes was selected and optimized to evaluate drug encapsulation performance of niosomes for further drug delivery adaptations by one of the chemotherapy drugs, paclitaxel (PTX). Cytotoxicity study was established with the most efficiently encapsulated niosomal condition with human‐derived fibroblasts (HDFs) and U‐87 as the representation of healthy and cancerous cell lines. Results demonstrated 1:100 diluted PTX‐loaded niosome in the certain concentration demonstrated favorable toxicity in U‐87 than original PTX at the same concentration while not disturbing healthy HDFs. These findings underscore the potential of niosomes for reliable drug delivery, challenging the dominance of liposomal vehicles and presenting economically viable nanocarriers with significant implications for advancing biomedical research.

16 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NCNilufer Cakir
Nilufer Cakir
NONaile Ozturk
Naile Ozturk
AKAsli Kara
Asli Kara
Ali ZarrabiAli Zarrabi
Ali Zarrabi
Nur MustafaogluNur Mustafaoglu
Nur Mustafaoglu
This study delves into the optimization of niosome production for biological applications, focusing on their emerging role as amphiphilic nanoparticles derived from nonionic surfactants, poised at the forefront of biomedical research. We aimed to formulate and characterize a diverse array of niosomal nanoparticles, with particular emphasis on process-related parameters and physicochemical characteristics. Critical thresholds for size, polydispersity, and zeta potential were established to identify parameters crucial for optimal niosomal formulations through a comprehensive investigation of concentrations, sonication times, ingredient ratios, and surfactant types. Leveraging MODDE® software, we generated ten optimized formulations from preliminary parameter screening. The proposed experimental model design by the software exhibited acceptable similarity to the obtained experimental results (F-score:0.83). The criteria for selection of the predicted experimental model formed based on targeted physicochemical considerations. To enhance half-life and penetration, especially in higher electrostatic regions like the Central Nervous System (CNS), we proposed a neutralized surface charge (−10 to 10 mV) while maintaining size within 100-200 nm and polydispersity below 0.5. Extended stability screening revealed periodic and extended Gaussian distributions for size and zeta potential to minimize flocculation and coagulation caused by neutralized surface charge. Notably, the cellular response performance of optimized niosomes was assessed via cellular binding, uptake, and viability in comparison to liposomes. Glioblastoma cell line (U-87) and granulocyte colony-stimulating factor (G-CSF) containing lymphoblastic leukemia cell line (NFS-60) were chosen to represent tumors developed in the CNS region and white blood cells, respectively, enabling a comprehensive comparative analysis with liposomes. The meticulous comparison between niosomes and liposomes revealed comparable cellular viability profiles on both U-87 and NFS-60 cell lines, highlighting their similarities in cellular interactions. Moreover, selected niosomal formulations demonstrated exceptional cellular uptake, either equaling or surpassing observed liposomal uptake. One of the most promising niosomes was selected and optimized to evaluate drug encapsulation performance of niosomes for further drug delivery adaptations by one of chemotherapy drugs, Paclitaxel (PTX). Cytotoxicity study was established with the most efficiently encapsulated niosome condition with human-derived fibroblasts (HDFs) and U-87 as the representation of healthy and cancerous cell lines. Results demonstrated 1:100 diluted PTX-loaded niosome in the certain concentration demonstrated favourable toxicity in U-87 than original PTX at the same concentration while not disturbing healthy HDFs. These findings underscore the potential of niosomes for reliable drug delivery, challenging the dominance of liposomal vehicles and presenting economically viable nanocarriers with significant implications for advancing biomedical research.